Durvalumab, a monoclonal antibody that binds to PD-L1, showed extended overall survival (OS) and progression-free survival (PFS) compared to a placebo for patients with limited-stage small cell lung cancer in a phase 3 ADRIATIC trial. The trial included 730 patients and evaluated durvalumab monotherapy, durvalumab plus tremelimumab-actl, or placebo. The primary endpoints of improved PFS and OS were met with durvalumab monotherapy. Secondary endpoints, including PFS and OS with durvalumab plus tremelimumab-actl, are still being analyzed. The safety profile of durvalumab was consistent with prior reports, with no new safety signals observed.
Source link
Durvalumab improves survival in limited-stage small cell lung cancer
